GLTO

Galecto, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website galecto.com
Employees(FY) 45
ISIN US36322Q2066

Performance

-11.82%

-20.34%

-65.94%

-61.73%

-73.89%

YTD

-69.17%

Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Advanced Technical Analysis

Technical Analysis of GLTO 2024-12-20

The stock exhibits a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. The Technical Score of 33 further reinforces the bearish outlook, highlighting a lack of momentum for upward movement in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GLTO

Stock Rank

Recent News & Updates

2024-11-13 20:55
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now(Yahoo Finance)
2024-10-31 20:30
Galecto Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-10-17 20:15
Galecto price target raised to $10 from $9 at Oppenheimer(Yahoo Finance)
2024-10-14 20:30
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler(Globenewswire)
2024-10-06 20:45
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines(Globenewswire)
2024-08-27 21:00
Galecto Announces Reverse Stock Split(Globenewswire)
2024-08-12 10:53
GLTO Stock Earnings: Galecto Beats EPS for Q2 2024(Investorplace)
2024-05-02 22:54
GLTO Stock Earnings: Galecto Beats EPS for Q1 2024(Investorplace)
2024-05-01 04:01
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab(Globenewswire)
2024-03-15 01:53
GLTO Stock Earnings: Galecto Beats EPS for Q4 2023(Investorplace)
2024-02-13 23:00
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?(Zacks)
2024-01-09 03:57
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock(Yahoo Finance)
2023-12-21 17:52
Galecto posts myelofibrosis data as search for savior continues, investors shrug(Fiercebiotech)
2023-12-21 03:05
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis(Globenewswire)
2023-10-22 20:00
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial(Globenewswire)
2023-09-27 21:49
Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls(Yahoo Finance)
2023-09-26 17:08
Galecto lays off 70%, hunts for 'strategic alternatives' in wake of fibrosis drug fail(Fiercebiotech)
2023-09-26 04:01
Galecto Announces Plans to Explore Strategic Alternatives(Yahoo Finance)
2023-08-30 23:00
Galecto to Present at Investor Conferences in September(Yahoo Finance)
2023-08-17 07:01
OrbiMed Advisors LLC Reduces Stake in Galecto Inc(Yahoo Finance)
2023-08-16 20:58
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More(Yahoo Finance)
2023-08-15 19:46
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails(Yahoo Finance)
2023-08-14 19:35
Galecto to discontinue development of lung disease treatment(Yahoo Finance)
2023-08-14 19:30
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis(Yahoo Finance)
2023-07-31 04:05
Galecto Reports Second Quarter Operating and Financial Results(Yahoo Finance)
2023-07-27 11:02
ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc(Yahoo Finance)
2023-07-24 21:59
These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts(Yahoo Finance)
2023-06-19 20:58
Galecto Set to Join Russell Microcap® Index(Yahoo Finance)
2023-05-29 20:00
Galecto to Present at the Upcoming Jefferies Healthcare Conference(Yahoo Finance)
2023-05-22 20:30
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.